Trial | NCT00356395  Report issue

Title

Safety and Effects of Ramipril Combined With Candesartan
Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    40
we hypothesized that combination therapy has additive beneficial effects to improve endothelial dysfunction and adipocytokine profiles in patients with hypertension.
Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms and two washout periods (each 2 months).
Study Started
Aug 31
2003
Study Completion
Mar 31
2006
Last Update
Jul 26
2006
Estimate

Drug ramipril, candesartan

Criteria 

Inclusion Criteria:

patients with mild to moderate hypertension

Exclusion Criteria:

We will exclude patients with severe hypertension, unstable angina, acute myocardial infarction, or renal insufficiency.
No Results Posted